CO2021011039A2 - Inhibidores de arginasa y métodos de uso de estos - Google Patents

Inhibidores de arginasa y métodos de uso de estos

Info

Publication number
CO2021011039A2
CO2021011039A2 CONC2021/0011039A CO2021011039A CO2021011039A2 CO 2021011039 A2 CO2021011039 A2 CO 2021011039A2 CO 2021011039 A CO2021011039 A CO 2021011039A CO 2021011039 A2 CO2021011039 A2 CO 2021011039A2
Authority
CO
Colombia
Prior art keywords
methods
compounds
formula
arginase inhibitors
arginase
Prior art date
Application number
CONC2021/0011039A
Other languages
English (en)
Inventor
Scott Nathan Mlynarski
Tyler Grebe
Sameer Kawatkar
Maurice Raymond Verschoyle Finlay
Iain Simpson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO2021011039A2 publication Critical patent/CO2021011039A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se divulgan compuestos de fórmula (Ib) o (Vc), o una sal farmacéuticamente aceptable de estos, composiciones farmacéuticas que comprenden compuestos de fórmula (Ib) o (Vc) y métodos para utilizar estos para tratar el cáncer, una enfermedad inflamatoria respiratoria e inhibir la arginasa: (Ib), o (Vc); donde R1 es -H o -C(O)CH(R1a)NHR1b; y R1a se selecciona entre -H, -alquilo (C1-C4) y CH2OR1c; R1b es -H; o como alternativa, R1a y R1b, junto con el átomo al que están unidos, forman un anillo heterocíclico de 5 miembros; y R1c es H o -CH3.
CONC2021/0011039A 2019-02-08 2021-08-23 Inhibidores de arginasa y métodos de uso de estos CO2021011039A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962802765P 2019-02-08 2019-02-08
PCT/IB2020/050982 WO2020161675A1 (en) 2019-02-08 2020-02-07 Arginase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
CO2021011039A2 true CO2021011039A2 (es) 2021-09-09

Family

ID=69770954

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0011039A CO2021011039A2 (es) 2019-02-08 2021-08-23 Inhibidores de arginasa y métodos de uso de estos

Country Status (29)

Country Link
US (1) US20220106335A1 (es)
EP (1) EP3921033B1 (es)
JP (1) JP2022521474A (es)
KR (1) KR20210126044A (es)
CN (1) CN113395996B (es)
AU (1) AU2020218651B2 (es)
BR (1) BR112021015581A2 (es)
CA (1) CA3127755A1 (es)
CL (1) CL2021002056A1 (es)
CO (1) CO2021011039A2 (es)
CR (1) CR20210463A (es)
DK (1) DK3921033T3 (es)
DO (1) DOP2021000166A (es)
EA (1) EA202192114A1 (es)
ES (1) ES2960034T3 (es)
FI (1) FI3921033T3 (es)
HR (1) HRP20231092T1 (es)
HU (1) HUE062968T2 (es)
IL (1) IL285108A (es)
LT (1) LT3921033T (es)
MA (1) MA56324B1 (es)
MX (1) MX2021009499A (es)
PE (1) PE20220280A1 (es)
PL (1) PL3921033T3 (es)
PT (1) PT3921033T (es)
RS (1) RS64781B1 (es)
SG (1) SG11202108503PA (es)
SI (1) SI3921033T1 (es)
WO (1) WO2020161675A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901572D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds
SE0300907D0 (sv) * 2003-03-31 2003-03-31 Astrazeneca Ab Novel compounds
CA2749853C (en) * 2009-01-26 2018-08-21 Trustees Of The University Of Pennsylvania Arginase inhibitors and methods of use
KR101931822B1 (ko) * 2010-04-22 2018-12-24 마아즈, 인코오포레이티드 아르기나아제의 억제제와 그것의 치료적 적용
EP3034509B1 (en) * 2010-10-26 2020-04-22 Mars, Incorporated Arginase inhibitors as therapeutics
AU2012326109A1 (en) * 2011-10-19 2014-05-29 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
EP3428153A1 (en) * 2012-12-17 2019-01-16 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
PL410665A1 (pl) * 2014-12-29 2016-07-04 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
WO2017175185A1 (en) * 2016-04-08 2017-10-12 Novartis Ag Heteroaryl butanoic acid derivatives as lta4h inhibitors
PT3559009T (pt) * 2016-12-22 2021-05-04 Calithera Biosciences Inc Composições e métodos para inibir a atividade da arginase
CN108794517B (zh) * 2017-04-27 2021-03-30 南京谷睿生物科技有限公司 一种精氨酸酶抑制剂及其制备方法与用途
WO2019205979A1 (zh) * 2018-04-27 2019-10-31 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途

Also Published As

Publication number Publication date
DOP2021000166A (es) 2021-09-30
US20220106335A1 (en) 2022-04-07
DK3921033T3 (da) 2023-10-16
BR112021015581A2 (pt) 2021-10-05
AU2020218651A1 (en) 2021-09-30
JP2022521474A (ja) 2022-04-08
SI3921033T1 (sl) 2023-11-30
AU2020218651B2 (en) 2023-01-12
MX2021009499A (es) 2021-09-08
WO2020161675A1 (en) 2020-08-13
EA202192114A1 (ru) 2021-12-01
HUE062968T2 (hu) 2023-12-28
RS64781B1 (sr) 2023-11-30
MA56324B1 (fr) 2023-10-31
SG11202108503PA (en) 2021-09-29
CR20210463A (es) 2021-10-15
CN113395996B (zh) 2024-05-28
PE20220280A1 (es) 2022-02-25
FI3921033T3 (fi) 2023-09-15
EP3921033A1 (en) 2021-12-15
CL2021002056A1 (es) 2022-03-04
PL3921033T3 (pl) 2024-01-15
CA3127755A1 (en) 2020-08-13
LT3921033T (lt) 2023-09-25
PT3921033T (pt) 2023-10-11
HRP20231092T1 (hr) 2023-12-22
IL285108A (en) 2021-09-30
ES2960034T3 (es) 2024-02-29
KR20210126044A (ko) 2021-10-19
CN113395996A (zh) 2021-09-14
EP3921033B1 (en) 2023-07-26

Similar Documents

Publication Publication Date Title
CL2020002096A1 (es) Inhibidores de arginasa y sus métodos de uso.
CO2021015698A2 (es) Moduladores de thr-β y métodos de uso de estos
PE20230238A1 (es) Inhibidores de kras g12c
PE20190329A1 (es) Compuestos moduladores de fxr (nr1h4)
CY1107221T1 (el) Παραγωγα τριαζολιου ως ανταγωνιστες υποδοχεα ταχυκινινης
CO6251294A2 (es) Derivados de 9-(pirazol-3-il)-9h-purin-2-amina y 3-(pirazol-3-il)-3h-imidazol4,5-b piridin-5-amina y su uso para el tratamiento del cancer
AR070531A1 (es) Inhibidores de cinasa pim y metodos para su uso
EA202092975A1 (ru) Селективные супрессоры рецептора эстрогена
PE20220705A1 (es) Derivados de 6,7-dihidro-5h-pirido[2,3-c]piridazin y compuestos relacionados como inhibidores de proteina bcl-xl y agentes proapoptoticos para el tratamiento del cancer
AR087212A1 (es) ANTAGONISTAS DE CRTh2
PE20190106A1 (es) Inhibidores del potenciador del homologo zeste 2
CO6400188A2 (es) Inhibidores de la fosfodiesterasa tipo iii (pdeiii) o agentes sensibilizantes al ca2+ para elt ratamiento de la cardiomiopatia hepertrófica
CO2021011039A2 (es) Inhibidores de arginasa y métodos de uso de estos
PE20220768A1 (es) Inhibidores de molecula pequena de quinasa inductora de nf-kb
RU2010115337A (ru) Трициклические гетероциклические производные
CL2022000893A1 (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
ECSP22027784A (es) Derivados de 2–azaespiro[3.4]octano como agonistas de m4
PE20210404A1 (es) Derivados de pirrolo [1,2-b] piridazina
EA201100476A1 (ru) Агонист глюкокортикоидного рецептора, содержащий новые производные 1,2,3,4-тетрагидрохиноксалина с фенильной группой, имеющей структуру эфира сульфоновой кислоты, введенной в нее в качестве заместителя
CO6180505A2 (es) Metodos para el tratamiento de transtornos cocleares y vestibulares
ECSP22054240A (es) Compuesto y composici?n como inhibidor de quinasa del receptor pdgf
EA202091886A1 (ru) Ингибиторы аргиназы и способы их применения
CY1112596T1 (el) Νεες ενωσεις και χρηση αυτων
AR114394A1 (es) Inhibidores de arginasa y sus métodos de uso
NZ767738B2 (en) Arginase inhibitors and methods of use thereof